ELI LILLY – Substantial growth began with the introduction of the first Insulin product

After more than 140 years in business, Eli Lilly has introduced more than a hundred medications for the treatment of patients. In 2022, metabolic drugs (diabetes, kidneys, etc.) will contribute the most to the sales with nearly 14.5 billion USD, representing nearly half of the organization’s total sales. In Vietnam, Eli Lilly has 42 drug registration numbers for injectable products such as Insulin lines (Insulin lispro, Insulin largine, and human Insulin), Gemcitabine, and Pemetrexed, as well as oral drugs such as Duloxetine, Prasugel, and Tadalafil…

Overview

In 1876, when the pharmaceutical market was flooded with unknown-origin drugs, Colonel Eli Lilly founded the company with a commitment to producing high-quality medications for patients. Eli Lilly still adheres to the Colonel’s vision in every aspect of its business operations, using his motto “Take what you find here and make it better and better”.

Development cooperation

Eli Lilly has a long history of collaboration with many researchers and universities. Currently, Eli Lilly is collaborating with prestigious universities such as the University of Kentucky, University of Pennsylvania, Louisiana State University, etc. to develop cancer treatment drugs. Recently, Eli Lilly’s Gateway Labs model has attracted and supported 15 biotechnology research units to conduct therapeutics research together.

R&D and production activities

The company’s first lab was established in Indianapolis. After more than 140 years in business, Eli Lilly has introduced more than a hundred medications for the treatment of patients. Currently, the company’s research and production facilities are located in seven countries with approximately 39,000 employees (2022). Cancer, metabolism (diabetes), neurological, infection, and immunity are the top five disease groups in terms of research and development expenditures. With nearly 14.5 billion USD in 2022, the metabolic drugs group contributes the most to the company’s sales, accounting for nearly half of total sales.

Regarding research technology, Eli Lilly holds 28 patents on injectable drugs, 4 patents on oral and inhaled drugs. Additionally, Eli Lilly possesses eleven new drug discovery technologies, focusing primarily on central nervous system drugs, infections, and cancer.

By researching Bebtelovimab, a drug to treat mild to moderate COVID patients, Eli Lilly also took part in the anti-COVID-19 campaign. In 2022, drugs to treat diabetes, cancer, neurology, and autoimmunity are introduced, and the launch of Mounjaro (tirzepatide) for type 2 diabetes yields many positive outcomes.

In Vietnam, Eli Lilly has 42 drug registration numbers, including 33 injection drugs and 9 oral drugs. Insulin (Insulin lispro, Insulin largine, and human Insulin), Gemcitabine, and Pemetrexed are some of Eli Lilly’s most prominent injectable drugs… Popular oral medications include Duloxetine, Prasugel, and Tadalafil.

Upcoming development plan

The company plans to launch four new drugs in 2023 and will continue to invest in research, production, and employee development. Concerning the Covid-19 pandemic, the company will continue to closely monitor the situation while developing new antibodies to help prevent hospitalization and death in COVID-19 patients.


REFERENCES:

  1. The legacy of Eli Lilly – The Pharmaceutical Journal (pharmaceutical-journal.com)
  2. Eli Lilly & Co. History, Insulin Price Hikes & Pending Lawsuits (drugwatch.com)
  3. The Story of Prozac: A Landmark Drug in Psychiatry | Psychology Today
  4. FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer | Eli Lilly and Company
  5. Top animal health companies by revenue worldwide 2022 | Statista
  6. The 15 All-Time Best-Selling Prescription Drugs | Kiplinger
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
error: Content is protected !!